Armata Pharmaceuticals, Inc.
ARMP NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$3.45
KIRA · Stoqly’s AI analyst, in plain words
- Armata Pharmaceuticals, Inc. had $4.9M of revenue in fiscal 2025, down 5.2% on the year before. Over five years, revenue changed +42.9% a year on average.
- Its operating margin was −747.0%, up 73.2 pts: of every 100 in sales, about −747 is left after running the business.
- Armata Pharmaceuticals, Inc. lost $174M in fiscal 2025.
- Free cash flow was −$26.3M in fiscal 2025, −536.4% of revenue.
Market cap
$214M
P/E
—
Revenue
$4.9M
Net income
−$174M
Free cash flow
−$26.3M
Operating margin
−747.0%
Armata Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−5.2%
No. Sales fell 5.2% last year.
Does it make a profit?
−3,544.0%
No. It lost money last year.
Does profit turn into cash?
−536.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Armata Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Armata Pharmaceuticals, Inc.
- CIK
- 0000921114
Armata Pharmaceuticals, Inc. · ARMP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.5M | $5.5M | $4.5M | $5.2M | $4.9M |
| Revenue growth | 443.6% | 23.1% | −17.8% | 14.2% | −5.2% |
| Operating margin | −532.5% | −670.8% | −902.8% | −820.2% | −747.0% |
| Net income | −$23.2M | −$36.9M | −$69.0M | −$18.9M | −$174M |
| Net margin | −517.5% | −670.2% | −1,524.5% | −365.6% | −3,544.0% |
| Diluted EPS | −$0.96 | −$1.08 | −$1.91 | −$0.89 | −$4.80 |
| Cash | |||||
| Cash from operations | −$23.6M | −$32.5M | −$47.4M | −$37.6M | −$25.8M |
| Capital expenditure | $1.3M | $2.2M | $8.1M | $1.9M | $0.5M |
| Free cash flow | −$24.9M | −$34.7M | −$55.6M | −$39.4M | −$26.3M |
| FCF margin | −556.1% | −629.8% | −1,226.9% | −762.1% | −536.4% |
| Share count change | 46.8% | 42.3% | 5.2% | 63.7% | −38.6% |
| Debt and strength | |||||
| Cash and short-term investments | $10.3M | $14.9M | $13.5M | $9.3M | $8.7M |
| Shareholders' equity | $25.4M | $36.1M | −$32.1M | −$48.0M | −$219M |
| Current ratio | 3.1x | 1.1x | 1.2x | 0.2x | 1.2x |
| Interest coverage | −372.2x | — | −15.6x | — | — |
| Returns and quality | |||||
| Return on equity | −104.6% | −120.1% | −3,439.4% | — | — |
| Return on tangible equity | −198.7% | −165.3% | — | — | — |
| Piotroski F-score | 3 | 1 | 2 | 2 | 4 |
| Altman Z'' | −10.2 | −10.0 | −13.1 | −18.8 | −25.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Armata Pharmaceuticals, Inc. · ARMP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.45 a share, the company is worth $214M.
Source: SEC EDGAR XBRL filings (CIK 0000921114). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.